The autoinjectors market is entering a decisive growth phase, moving from a niche delivery format into mainstream healthcare infrastructure at a pace few medical device categories can match. This surge is being fueled by a convergence of factors: a rapidly rising global chronic disease burden, the explosive growth of GLP-1 based obesity and diabetes therapies, an aging population that...